aTyr Pharma (ATYR) is a pre-revenue clinical-stage biopharmaceutical company with a single lead asset, efzofitimod, targeting pulmonary sarcoidosis, SSc-ILD, and other interstitial lung diseases. Under a liquidation lens, the company presents deeply negative equity recovery. MFFAIS reports a cash liquidation value of approximately -$25.9M, a liquid liquidation value of -$25.0M, and an operating liquidation value of -$25.0M as of the March 31, 2026 period end. These figures indicate that even after applying 100% recovery to cash and near-cash assets, total liabilities exceed liquidatable assets, leaving zero residual for equity holders on a wind-down basis. The primary value-destruction mechanism is the standard clinical-stage biotech asymmetry: all tangible assets (predominantly cash and short-term investments) are partially consumed by accumulated lease obligations, accrued clinical trial commitments, and accounts payable that survive at face value in liquidation, while intangible assets — the tRNA synthetase platform, efzofitimod IP, and all regulatory and clinical data — receive zero haircut-adjusted recovery. A material negative development in this filing period is the May 12, 2026 termination notice received from Kyorin Pharmaceutical under the Kyorin Agreement. Kyorin exercised its no-cause termination right effective 90 days from notice. This eliminates the company's only active collaboration revenue stream and forfeits $155.0M in aggregate contingent milestone payments plus tiered royalties on Japanese net sales. The company received $20.0M in aggregate upfront and milestone consideration over the life of the deal, which is now fully concluded with no further inflows. This termination also reloads aTyr with full global commercialization responsibility for efzofitimod at a time when the company is under Nasdaq minimum bid price deficiency notice (received December 4, 2025, compliance date June 2, 2026). The stock traded between $0.65 and $6.61 between January 1, 2025 and May 11, 2026, signaling significant market-assigned probability of capital access impairment. The company did not utilize its ATM facility (capacity up to $215M inclusive of prior sales) during Q1 2026. Stockholders approved a doubling of authorized shares from 170M to 340M on May 11, 2026, confirming management's expectation of substantial future equity issuance. A securities class action filed in October 2025 against the CEO and CFO adds a contingent liability not separately quantified in this filing. The filing does not separately disclose operating lease ROU asset and liability balances, accrued CRO/CDMO commitments, or the specific cash and investment balance as of March 31, 2026 in the narrative body provided; those figures would require the balance sheet exhibit, which is not included in the provided filing body. TAG_CONTEXT is empty, indicating no XBRL tags were surfaced for this filing in the input set.
▼ Community Notes